XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Bioniz
Common Stock
Common Stock
Bioniz
Additional Paid-in Capital
Additional Paid-in Capital
Bioniz
Accumulated Other Comprehensive Income
Accumulated Deficit
Balance at Dec. 31, 2021 $ 66,505   $ 2   $ 176,618   $ (138) $ (109,977)
Balance, Shares at Dec. 31, 2021     29,455,668          
Issuance of common stock   $ 22,542   $ 1   $ 22,541    
Issuance of common stock, Shares       4,820,230        
Vesting of restricted stock liability 18       18      
Stock-based compensation expense 1,298       1,298      
Other comprehensive income (loss) (316)           (316)  
Net loss (37,417)             (37,417)
Balance at Mar. 31, 2022 52,630   $ 3   200,475   (454) (147,394)
Balance, Shares at Mar. 31, 2022     34,275,898          
Balance at Dec. 31, 2021 66,505   $ 2   176,618   (138) (109,977)
Balance, Shares at Dec. 31, 2021     29,455,668          
Other comprehensive income (loss) 331              
Net loss (65,201)              
Balance at Sep. 30, 2022 28,160   $ 3   203,142   193 (175,178)
Balance, Shares at Sep. 30, 2022     34,352,084          
Balance at Mar. 31, 2022 52,630   $ 3   200,475   (454) (147,394)
Balance, Shares at Mar. 31, 2022     34,275,898          
Issuance of common stock under employee stock purchase plan 141       141      
Issuance of common stock under employee stock purchase plan, Shares     76,186          
Vesting of restricted stock liability 18       18      
Stock-based compensation expense 1,302       1,302      
Other comprehensive income (loss) 305           305  
Net loss (14,129)             (14,129)
Balance at Jun. 30, 2022 40,267   $ 3   201,936   (149) (161,523)
Balance, Shares at Jun. 30, 2022     34,352,084          
Vesting of restricted stock liability 17       17      
Stock-based compensation expense 1,189       1,189      
Other comprehensive income (loss) 342           342  
Net loss (13,655)             (13,655)
Balance at Sep. 30, 2022 28,160   $ 3   203,142   193 (175,178)
Balance, Shares at Sep. 30, 2022     34,352,084          
Balance at Dec. 31, 2022 31,942   $ 3   204,268   76 (172,405)
Balance, Shares at Dec. 31, 2022     34,414,149          
Stock-based compensation expense 1,038       1,038      
Other comprehensive income (loss) 229           229  
Net loss (3,940)             (3,940)
Balance at Mar. 31, 2023 29,269   $ 3   205,306   305 (176,345)
Balance, Shares at Mar. 31, 2023     34,414,149          
Balance at Dec. 31, 2022 31,942   $ 3   204,268   76 (172,405)
Balance, Shares at Dec. 31, 2022     34,414,149          
Common stock repurchased,Shares     298,385          
Common stock repurchased     $ 300          
Other comprehensive income (loss) 382              
Net loss (10,993)              
Balance at Sep. 30, 2023 24,108   $ 3   207,045   458 (183,398)
Balance, Shares at Sep. 30, 2023     35,119,248          
Balance at Mar. 31, 2023 29,269   $ 3   205,306   305 (176,345)
Balance, Shares at Mar. 31, 2023     34,414,149          
Issuance of common stock under employee stock purchase plan 86       86      
Issuance of common stock under employee stock purchase plan, Shares     154,351          
Stock-based compensation expense 934       934      
Other comprehensive income (loss) 35           35  
Net loss (3,343)             (3,343)
Balance at Jun. 30, 2023 26,981   $ 3   206,326   340 (179,688)
Balance, Shares at Jun. 30, 2023     34,568,500          
Issuance of common stock, Shares       849,133        
Common stock repurchased,Shares     (298,385)          
Common stock repurchased 260       (260)      
Stock-based compensation expense 979       979      
Other comprehensive income (loss) 118           118  
Net loss (3,710)             (3,710)
Balance at Sep. 30, 2023 $ 24,108   $ 3   $ 207,045   $ 458 $ (183,398)
Balance, Shares at Sep. 30, 2023     35,119,248